Linked e-resources
Details
Table of Contents
Introduction (Anne Bremer and Roger Strand)
Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen)
Chapter 2. Cancer biomarkers from a patient's perspective (Karen Gissum)
Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås)
Chapter 4. HER2: an apparently 'simple' biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen)
Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti)
Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand)
Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg)
Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand)
Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck)
Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand)
Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns)
Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang)
Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal)
Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).
Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen)
Chapter 2. Cancer biomarkers from a patient's perspective (Karen Gissum)
Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås)
Chapter 4. HER2: an apparently 'simple' biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen)
Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti)
Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand)
Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg)
Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand)
Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck)
Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand)
Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns)
Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang)
Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal)
Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).